descriptive
Analysis v1
32
0
Liver transplant patients with fatty liver disease who took saroglitazar saw a small increase in belly fat and fat under the skin. This finding is from the abstract summary - full study details were not available
Scientific Claim
A mild increase in visceral adipose tissue and abdominal subcutaneous adipose tissue was observed in liver transplant recipients with NAFLD treated with saroglitazar.
Original Statement
“did lead to a mild increase in visceral adipose tissue and abdominal subcutaneous adipose tissue.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The single-arm study design cannot establish causation; the increase should be described as observed or associated.
Evidence from Studies
Supporting (1)
32
32
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
Cross-Sectional Study
Human
2023 Sep 1Contradicting (0)
0
No contradicting evidence found